Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive beads show promise for liver tumors in french registry

NCT ID NCT03256994

Disease control Sponsor: Cardiovascular and Interventional Radiological Society of Europe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed registry tracked 332 liver cancer patients in France who received SIR-Spheres, tiny radioactive beads injected into the liver's blood supply to target tumors. The goal was to see how this treatment is used in everyday practice and to monitor safety and survival. Results will help guide future use and reimbursement decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yttrium-90 loaded SIR-Spheres microspheres (radioactive beads delivered via catheter to liver tumors)
What this could lead to
If results are positive, this could confirm that SIR-Spheres are a safe and effective option for controlling liver tumors in real-world practice.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

332 people

The number who actually took part.

Started

Aug 2017

Finished

Jul 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In a general manner and according to the Intent-To-Treat principle, no subject will be excluded from the analysis. The primary and secondary endpoint analysis will include all enrolled subjects in CIRT-FR. However, patients who are considered for SIR-Spheres treatment but for whom it was decided that they would not be treated will not be included in the analysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Primary or secondary liver tumours * Treatment of liver tumours with SIR-Spheres * Signed informed consent form Exclusion Criteria: \- Consent denied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer

Contacts and locations

Locations

  • CHRU de Strasbourg

    Strasbourg, France

  • CHU d'Angers

    Angers, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Grenoble Alpes

    Grenoble, France

  • CHU de Lyon

    Lyon, France

  • CHU de Nimes

    Nîmes, France

  • CHU de Poitiers

    Poitiers, France

  • Centre Léon Bérard

    Lyon, France

  • Chu de Dijon

    Dijon, France

  • Hôpital Beaujon

    Clichy, France

  • Hôpital Henri Mondor

    Créteil, France

  • Institut Gustave Roussy

    Paris, France

  • Institut Paoli-Calmettes

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.